drugset / Trial / NCT04610892
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
Timeline
- Start
- 2020-11-04
- Primary completion
- 2023-11-08
- Completion
- 2023-11-08
Outcome
Missed primary endpoint
registry analysis (superiority test); MEDI6570 50 mg vs Placebo; p = 0.065; NCT04610892 ↗
registry analysis (superiority test); MEDI6570 150 mg vs Placebo; p = 0.747; NCT04610892 ↗
registry analysis (superiority test); MEDI6570 400 mg vs Placebo; p = 0.563; NCT04610892 ↗
registry analysis (superiority test); MEDI6570 150 mg or 400 mg vs Placebo; p = 0.685; NCT04610892 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GOLOCDACIMAB | Monoclonal antibody | — | Subcutaneous |